An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 positive human sera

Journal of Virological Methods

Volumn 71, Issue 1, 1998, Pages 7-16

  Gómez, Carmen E ^a   López Campistrous, Ana E ^a   Duarte, Carlos A ^a  

^a Division de Vacunas   (Cuba)

Author keywords

Bovine serum albumin; ELISA; HIV 1; Serology; V3 peptides

Indexed keywords

BOVINE SERUM ALBUMIN; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE; VIRUS GLYCOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; NONHUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CATTLE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOASSAY; MOLECULAR SEQUENCE DATA; PEPTIDE BIOSYNTHESIS; PEPTIDE FRAGMENTS; RABBITS; SERUM ALBUMIN, BOVINE;

ANIMALIA; BOVINAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS; RNA VIRUSES;

EID: 0345055309     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(97)00196-1     Document Type: Article

References (34)

1. Baillou A., Brand D., Denis F., Boup S.M., Chout R., Goudeau A., Barin F. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120. AIDS Res. Hum. Retroviruses. 9(12):1993;1209-1215.
2. Barin F., Lahbabi Y., Buzelay L., Lejeune B., Baillou-Beaufils A., Denis F., Mathiot C., M'Boub S., Vithayasai V., Dietrich U., Goudeadu A. Diversity of antibody binding to V3 peptides representing consensus sequences if HIV type 1 phenotypes A to E: An approach for HIV type 1 serological subtyping. AIDS Res. Hum. Retroviruses. 12(13):1996;1279-1289.
3. Carrow E.N., Vujcic L.K., Glass W.L., Seamon K.B., Rastog S.C., Hendry R.M., Boulos N., Nzila N., Quinnan G. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1 MN in sera from Africa and the Americas. AIDS Res. Hum. Retroviruses. 7(10):1991;831-838.
4. Cheingsow-Popov R., Lister S., Callow D., Kaleebu P., Beddows S., Weber J. The WHO Network for HIV isolation and characterization. AIDS Res. Hum. Retroviruses. 10(11):1994;1379-1386.
5. Duarte C.A., Montero M., Seralena A., Valdés R., Jiménez V., Benítez J., Narciandi E., Madrazo J., Padrón G., Sánchez G., Gjilliam G., Pearson C., Domínguez M.C., Wharen B., Menéndez A. Multiepitope polypeptide of the HIV-1 envelope induces monoclonal antibodies against V3 loop. AIDS Res. Hum. Retroviruses. 10(3):1994;235-243.
6. Duarte C.A., Pérez L., Vázquez J., Dueñas M., Vilarubia O.L., Navea L., Valdés R., Reyes O., Montero M., Ayala M., Gavilondo J. Epitope mapping, V region DNA sequence, and neutralizing Fab fragments of two monoclonal antibodies against the HIV-1 V3 loop. Immunotechnology. 2:1996;11-20.
7. Esparza J., Osmanov S., Heyward W.L. HIV Preventive Vaccines. Progress to date. Drugs. 50:1995;792-804.
8. Gnann J.W., McCormick J.B., Mitchell S., Nelson J., Oldstone M., Nelson J. Synthetic peptide Immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science. 237:1987;1346-1348.
9. Hart M.K., Palker T.J., Matthews T.J., Langlois A.J., Lerche N.W., Martin M.E., Scearce R.M., McDanal C., Bolognesi D.P., Haynes B. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J. Immunol. 146(8):1990;2677-2685.
10. Houghten R.A. General method for the rapid synthesis of large number of peptides. Specificity of antigen antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. U.S.A. 82:1985;5131.
11. Hudecz F., Price M.R. Monoclonal antibody binding to peptide epitopes conjugated to synthetic branched chain polypeptide carriers. Influence of the carrier upon antibody recognition. J. Immunol. Methods. 147:1992;201-210.
12. Javaherian K., Langlois A.J., McDanal C., Ross K.L., Eckler L.I., Jellis C.L., Profy A.T., Rusche J.R., Bolognesi D.P., Putney S.D., Mathews T.C. Principal neutralizing domain of the HIV-1 envelope protein. Proc. Natl. Acad. Sci. U.S.A. 86:1989;6768-6772.
13. Javaherian K., Langlois A.J., La Rosa G.J., Profy A.T., Bolognesi D.P., Herlihy W.C., Putney S.D., Mathews T.C. Broadly Neutralizing Antibodies Elicited by the Hipervariable Neutralizing Determinant of HIV-1. Science. 250:1990;1590.
14. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature. 227:1970;680-685.
15. Laman J.D., Schellekens M.M., Lewis G.K., Moore J.P., Matthews T.J., Langedijk J.P., Meloen R., Boersma W.J.A., Claaseen E. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody. AIDS Res. Hum. Retroviruses. 9(7):1993;605-612.
16. Lawoko A., Johansson B., Dash R., Falck L., Dietrich U., Pipkorn R., Nilehn B., Blomberg J. Continuity and discontinuity in the Anti V3 IgG response of human immunodeficiency virus Type 1-infected persons in a cross-sectional and longitudinal study using synthetic peptides. J Infect Dis. 172:1995;682-690.
17. López-Campistrous, A., Reyes, O., Garay, H., Duarte, C., 1996. Preferential recognition of V3 African sequences and relation with disease progression among Cuban HIV positive individuals. XI Internacional Conference on AIDS, Vancouver, Abstract Pub. A. 1010.
18. Lowry O.H. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
19. Marsden H.S., Owsianka A.M., Graham S., McLean G.W., Robertson C.A., Subak-Sharpe J.H. Advantages of branched peptides in serodiagnosis. Detection of HIV antibodies and the use of glycine spacers to increase sensitivity. J. Immunol. Methods. 147:1992;65-72.
20. Menéndez, A., Montero, M., Quintana, D., Gómez, C., Navea, L., Vilarubia, O., Carpio, E., Hayes, O., Duarte, C., 1996. V3 Multi-Epitope Polypeptides. The number of V3 regions affects the exposition of epitopes and the immunogenicity. XI Internacional Conference on AIDS, Vancouver, Abstract Tu.A.2104.
21. Montero M., Menéndez A., Domínguez M.C., Navea L., Vilarubia O.L., Quintana D., Izquierdo M., Jiménez V., Reyes O., Lobaina L., Noa E., Duarte C.A. Broadly reactive antibodies against a gp 120 V3-loop Multi-Epitope Polypeptide neutralize different isolates of Human Immunodeficiency Virus type 1 (HIV-1). Vaccine. 15(11):1997;1200-1208.
22. Moore J.P., Cao Y., Conley A.J., Wyatt R., Robinson J., Gorny M., Zolla-Pazner S., Ho D.D., Koup R.A. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid phase peptide binding assays. J. Acquired Immune Defic. Syndr. 7:1993;332-339.
23. Moore J.P. The reactivities of HIV-1+ human sera with solid phase V3 loop peptides can be poor predictors of their reactivities with the V3 loops on native gp120 molecules. AIDS Res. Hum. Retroviruses. 9(3):1993;209-218.
24. Myers G., Korber B., Wain-Hobson S., Smith R., Pavlakis G.N. (Eds.), 1994. Human Retroviruses and AIDS. A Compilation and Analysis of Nucleic Acid and Animo Acid Sequences, Theoretical Biology and Biophysics Group T-10, Mail Stop K710, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA.
25. Närvänen A., Korkolaínen M., Suni J., Korpela J., Kontio S., Partanen P., Vaheri A., Huhtala A.L. Synthetic env gp41 peptide as a sensitive and specific diagnostic reagent in different stages of human immunodeficiency virus type 1 infection. J. Med. Virol. 26:1988;111-118.
26. Neurath R., Jiang S., Strick N., Kolbe H., Kieny M., Muchmore E., Girard M. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full length V3 hypervariable loops of HIV-1 envelope glycoproteins. AIDS Res. Hum. Retroviruses. 7(10):1991;813-823.
27. Palker T.J., Clark M., Langloise A.J., Mathews T.J., Weinhold K.J., Randall R.R., Bolognesi D., Haynes B.F. Type specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. U.S.A. 85:1988;1932-1936.
28. Pau C.P., Lee-Thomas S., Auwanit W., George J.R., Ou C.Y., Parekh B.S., Granade T.C., Holloman D.L., Phillips S., Schochetman, Young N.L., Takebe Y., Gayle H.D., Weninger B.C. Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS. 7:1993;337-340.
29. Price M.R., Sekowski M., Hooi D.S.W., Durrant L.G., Hudecz F., Tendler S.J.B. Measurement of antibody binding to antigenic peptides conjugated in situ to albumin-coated microtitre plates. J. Immunol. Methods. 159:1993;277-281.
30. Putney, S.D., LaRosa, G.J., Profy, A.T., Silve, S., Scott, C.F., Javaherian, K., Robinson, J., Langlois, A.J., Matthews, T.J., Bolognesi, D.P., Lewis, J.A., Emini, E.A., 1991. HIV-1 principal neutralization determinant elicits broadly neutralizing antibodies. In Brown, F., Chanock, R.M., Lerner, R.A. (Eds.), Vaccines 91. Cold Spring Harbor Laboratory Press, New York.
31. Sherefa K., Sallberg M., Sonnerborg A. Evidence of no change in V3 loop antibody recognition pattern in HIV 1-infected Ethiopians between 1988 and 1993. AIDS Res. Hum. Retroviruses. 10(11):1994;1551-1556.
32. Towbin H.T., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrilamide gel to nitrocellulose sheets procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 76:1979;4350-4354.
33. Wasi C., Herring B., Raktham S., Vanichsen, Mastro T.D., Young N.L., Rubsamen-Waigmann H., von Briesen H., Kalish M.L., Luo C.C., Pau C.P., Baldwin A., Mullins J.I., Delwast E.L., Esparza J., Heyward W.L., Osmanov S. Determination of HIV subtypes in injecting drug users in Bangkok, Thailand using peptide enzyme immunoassay and the heteroduplex mobility assay: Evidence of increasing infection with HIV-1 subtype E. AIDS. 9(8):1995;843-851.
34. Zwart G., Back N.K.T., Ramautarsing C., Valk M., van der Hoek L., Goudsmit J. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. AIDS Res. Hum. Retroviruses. 10(3):1994;245-251.